No abstract available
Keywords:
blastic phase CML; dasatinib; sudden blastic transformation; treatment-free remission; tyrosine kinase inhibitor.
Publication types
-
Case Reports
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Female
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
-
Lymphocyte Activation*
-
Middle Aged
-
Protein Kinase Inhibitors / therapeutic use
-
Remission Induction / methods
-
Withholding Treatment
Substances
-
Protein Kinase Inhibitors